Literature DB >> 17489034

Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.

Hubert Mönnikes1, Bernd Pfaffenberger, Gudrun Gatz, Jasper Hein, Karna Dev Bardhan.   

Abstract

BACKGROUND/AIMS: A prime concern for gastroesophageal reflux disease (GERD) patients is fast symptom control. Sparse valid information is available on the rapidity of the effect of proton pump inhibitors in providing symptom relief. The new reflux questionnaire ReQuest is validated for daily assessment of changes in GERD symptoms. Therefore, this study investigated the efficacy of 20 mg pantoprazole and 20 mg esomeprazole with regard to the time to symptom relief in patients with endoscopy-negative GERD (enGERD) using ReQuest.
METHODS: 529 patients were treated with pantoprazole or esomeprazole over 4 weeks. ReQuest symptom scores were assessed daily. The mean and median times to first and sustained symptom relief were determined.
RESULTS: Median time to first symptom relief was 2 days for both drugs (intention-to-treat population). The median time to sustained symptom relief was 3 days shorter with pantoprazole (10.0 vs. 13.0 days). The Hodges-Lehmann estimator for the difference in time to reach first and sustained symptom relief between both groups was 0.00 days. For both variables the one-sided 95% CI (Moses) was [0.00; infinity[, documenting no significant differences between the treatment groups.
CONCLUSIONS: The rapidity of symptom control can be evaluated by clinically significant parameters using ReQuest. Pantoprazole and esomeprazole are equally effective in the time to first and sustained symptom relief. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17489034     DOI: 10.1159/000101084

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.

Authors:  Hubert Mönnikes; Robert C Heading; Holger Schmitt; Hubert Doerfler
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 2.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS)--is it one disease or an overlap of two disorders?

Authors:  Anita Gasiorowska; Choo Hean Poh; Ronnie Fass
Journal:  Dig Dis Sci       Date:  2008-12-10       Impact factor: 3.199

4.  Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.

Authors:  Robert C Heading; Hubert Mönnikes; Anne Tholen; Holger Schmitt
Journal:  BMC Gastroenterol       Date:  2011-05-11       Impact factor: 3.067

5.  Development and Psychometric Assessment of a Self-evaluation Questionnaire for Gastroesophageal Reflux Disease.

Authors:  Hye-Kyung Jung; Myung-Gyu Choi; Myung-Ki Baek; Justin C Y Wu
Journal:  J Neurogastroenterol Motil       Date:  2018-10-01       Impact factor: 4.924

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.